Rigshospitalet

Running trials

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Recruiting

  A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· Phase 3· Source

• Recruiting

  A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis

  2024-512914-16-00· Phase 3· Source

• Active, not recruiting

  A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

  NCT07018700· Phase 3· Source

• Active, not recruiting

  A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

  NCT07018713· Phase 3· Source

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Source

• Recruiting

  Thrombolysis in Factor Xa-inhibitors Trial

  NCT06878066· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

  NCT06641466· Phase 3· Source

• Recruiting

  A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma

  NCT06792422· Phase 4· Source

• Active, not recruiting

  Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

  NCT06627179· Phase 2· Source

• Active, not recruiting

  A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

  NCT06602479· Phase 2· Source

• Recruiting

  A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06635148· Phase 2/3· Source

• Active, not recruiting

  DAPHNE

  2024-510746-14-00· Phase 4· Source

• Active, not recruiting

  Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

  NCT06141473· Phase 3· Source

• Active, not recruiting

  Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

  NCT04688788· Phase 3· Source

• Active, not recruiting

  Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

  NCT04794101· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

  NCT04544449· Phase 3· Source

• Active, not recruiting

  An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS

  2023-507906-15-00· Phase 3· Source

• Recruiting

  Panguian

  2023-503474-20-00· Phase 4· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration2 recruiting
• Multiple sclerosis2 recruiting
• Atrial fibrillation1 recruiting
• Glaucoma1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy. (SNAP)

  NCT04054830· Phase 4· Source

• Recruiting

  Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis

  2023-504358-36-00· Phase 3· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

  NCT05518123· Phase 4· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

  NCT05509400· Phase 4· Source

• Completed

  A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

  NCT05452239· Phase 4· Source

• Active, not recruiting

  A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

  NCT05123703· Phase 3· Source

• Completed

  Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM)

  2024-517128-21-02· Phase 4· Source

• Completed

  A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration

  NCT04757610· Phase 3· Source

• Recruiting

  Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells

  NCT04957329· Phase 4· Source

• Completed

  A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

  NCT04686136· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

  NCT04548999· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

  NCT04544436· Phase 3· Source

• Completed

  Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy. (SNAP)

  2024-511820-15-03· Phase 4· Source

• Completed

  Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

  NCT03850782· Phase 3· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

  NCT03523858· Phase 3· Source